All Updates

All Updates

icon
Filter
Funding
Elevation Oncology announces USD 50 million underwritten public offering
Precision Medicine
Jun 8, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Funding
Apaleo raises EUR 20 million in growth equity funding to accelerate expansion
Travel Tech
Yesterday
Partnerships
Acai Travel partners with Hopper to enhance call center operations with AI technology
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Jun 8, 2023

Elevation Oncology announces USD 50 million underwritten public offering

Funding

  • Clinical-stage biopharma company Elevation Oncology announced an underwritten public offering of 17.8 million common shares and pre-funded warrants to purchase up to 4.4 million common shares. The company is targeting to raise gross proceeds of approximately USD 50 million at a price of USD 2.25 per share. The offering window is expected to close on June 15, 2023.

  • The net proceeds from the offering will primarily be used to fund the clinical development of EO-3021, Elevation Oncology's lead product candidate, which is an antibody-drug conjugate designed to target cancer cells expressing Claudin 18.2. The funds will also be used for general corporate purposes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.